222 related articles for article (PubMed ID: 30405097)
21. Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S.
Campello E; Spiezia L; Radu CM; Bulato C; Gavasso S; Tormene D; Woodhams B; Dalla Valle F; Simioni P
Thromb Haemost; 2016 Jan; 115(1):81-8. PubMed ID: 26354831
[TBL] [Abstract][Full Text] [Related]
22. Associations between complement pathways activity, mannose-binding lectin, and odds of unprovoked venous thromboembolism.
Høiland II; Liang RA; Hindberg K; Latysheva N; Brekke OL; Mollnes TE; Hansen JB
Thromb Res; 2018 Sep; 169():50-56. PubMed ID: 30015228
[TBL] [Abstract][Full Text] [Related]
23. Hypercoagulability and other risk factors in trauma intensive care unit patients with venous thromboembolism.
Van Haren RM; Valle EJ; Thorson CM; Jouria JM; Busko AM; Guarch GA; Namias N; Livingstone AS; Proctor KG
J Trauma Acute Care Surg; 2014 Feb; 76(2):443-9. PubMed ID: 24398771
[TBL] [Abstract][Full Text] [Related]
24. Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma.
Papageorgiou C; Vandreden P; Marret E; Bonnet F; Robert F; Spyropoulos A; Galea V; Elalamy I; Hatmi M; Gerotziafas GT
Thromb Res; 2013 Nov; 132(5):584-91. PubMed ID: 24094602
[TBL] [Abstract][Full Text] [Related]
25. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia.
Wichers IM; Tanck MW; Meijers JC; Lisman T; Reitsma PH; Rosendaal FR; Büller HR; Middeldorp S
Thromb Haemost; 2009 Mar; 101(3):465-70. PubMed ID: 19277406
[TBL] [Abstract][Full Text] [Related]
26. Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology.
Zakai NA; Lutsey PL; Folsom AR; Heckbert SR; Cushman M
Thromb Haemost; 2010 Aug; 104(2):207-12. PubMed ID: 20431849
[TBL] [Abstract][Full Text] [Related]
27. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Al-Ani F; Bermejo JM; Mateos MV; Louzada M
Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
[TBL] [Abstract][Full Text] [Related]
28. Increased activity of procoagulant factors in patients with small cell lung cancer.
Pedersen S; Kristensen AF; Falkmer U; Christiansen G; Kristensen SR
PLoS One; 2021; 16(7):e0253613. PubMed ID: 34288927
[TBL] [Abstract][Full Text] [Related]
29. Influence of single nucleotide polymorphisms on thrombin generation in factor V Leiden heterozygotes.
Segers O; Simioni P; Tormene D; Castoldi E
Thromb Haemost; 2014 Mar; 111(3):438-46. PubMed ID: 24226152
[TBL] [Abstract][Full Text] [Related]
30. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.
Almasi M; Sevcikova S; Slaby O; Kaisarova P; Maisnar V; Penka M; Pika T; Pour L; Radocha J; Scudla V; Svachova H; Hajek R
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):414-20. PubMed ID: 21859556
[TBL] [Abstract][Full Text] [Related]
31. Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.
Dennis J; Truong V; Aïssi D; Medina-Rivera A; Blankenberg S; Germain M; Lemire M; Antounians L; Civelek M; Schnabel R; Wells P; Wilson MD; Morange PE; Trégouët DA; Gagnon F
J Thromb Haemost; 2016 Oct; 14(10):1960-1970. PubMed ID: 27490645
[TBL] [Abstract][Full Text] [Related]
32. Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.
Isoda A; Sato N; Miyazawa Y; Matsumoto Y; Koumoto M; Ookawa M; Sawamura M; Matsumoto M
Int J Hematol; 2015 Sep; 102(3):271-7. PubMed ID: 26177588
[TBL] [Abstract][Full Text] [Related]
33. Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial.
Ramberg C; Hindberg K; Biedermann JS; Cannegieter SC; van der Meer FJ; Snir O; Leebeek FWG; Kruip MJHA; Hansen JB; Lijfering WM
J Thromb Haemost; 2022 Apr; 20(4):877-887. PubMed ID: 34953155
[TBL] [Abstract][Full Text] [Related]
34. Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Crowley MP; Kevane B; O'Shea SI; Quinn S; Egan K; Gilligan OM; Ní Áinle F
Clin Appl Thromb Hemost; 2016 Sep; 22(6):554-62. PubMed ID: 26759370
[TBL] [Abstract][Full Text] [Related]
35. Incidence of thromboembolism and associated factors in multiple myeloma patients treated with immunomodulatory drugs: a retrospective analysis in Belo Horizonte, Brazil.
da Costa IHF; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
Support Care Cancer; 2023 Dec; 32(1):35. PubMed ID: 38103099
[TBL] [Abstract][Full Text] [Related]
36. Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients.
Leiba M; Malkiel S; Budnik I; Rozic G; Avigdor A; Duek A; Nagler A; Kenet G; Livnat T
Blood Cells Mol Dis; 2017 Jun; 65():1-7. PubMed ID: 28365523
[TBL] [Abstract][Full Text] [Related]
37. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
Shin J; Lee JJ; Kim K; Min CK; Lee JO; Suh C; Kim JS; Lee YJ; Yoon SS; Jo JC; Lee HS; Bang SM;
Int J Hematol; 2019 Jan; 109(1):79-90. PubMed ID: 30291558
[TBL] [Abstract][Full Text] [Related]
38. Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
Sonnevi K; Tchaikovski SN; Holmström M; Rosing J; Bremme K; Lärfars G
Thromb Haemost; 2011 Nov; 106(5):901-7. PubMed ID: 21947267
[TBL] [Abstract][Full Text] [Related]
39. Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: A prospective cohort study.
Park MS; Spears GM; Bailey KR; Xue A; Ferrara MJ; Headlee A; Dhillon SK; Jenkins DH; Zietlow SP; Harmsen WS; Ashrani AA; Heit JA
J Trauma Acute Care Surg; 2017 Sep; 83(3):381-387. PubMed ID: 28362683
[TBL] [Abstract][Full Text] [Related]
40. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
